

Opening Ceremony World Health Summit 2021, Speech Stefan Oelrich

Stefan Oelrich is a member of the Board of Management of Bayer AG and head of the Pharmaceuticals Division, headquartered in Berlin, Germany, since November 1, 2018.

(08:22): For us therefore, we're really taking that leap us as a company Bayer, in cellular gene therapy, which to me is one of these examples where really we're going to make a difference hopefully moving forward, there's some ultimately the mRNA vaccines are an example for that cell in gene therapy. I always like to say if we had surveyed two years ago in the public, would you be willing to take a gene or cell therapy and inject it into your body, we would have probably had a 95 percent refusal rate. I think this pandemic has also opened many people's eyes to innovation in the way that was maybe not possible before.

Full "RAW" Transcript:

00:01 i now have the great pleasure to 00:03 announce stefan ulrich 00:05 he is member of the board

00:08 of management at bayer

00:10 and he's also president for the

00:11 pharmaceutical 00:13 section of bayer stefan please come up 00:16 you don't have to wait 00:18 and 00:19 i know him from quite a few interactions 00:21 and i know that he's a very globally 00:23 thinking 00:25 and 00:25 research and development and 00:27 innovation-minded person and therefore 00:30 i'm very interested to hear what stefan 00:32 has to tell us now the floor is yours 00:37 well thank you thank you axel 00:42 libra here professor gunn lieber axel 00:44 priest 00:46 distinguished guests ladies and 00:48 gentlemen 00:49 first of all it's really an honor and a 00:51 privilege to be up here talking to you 00:53 indeed axel and i uh 00:56 share a lot of time during the year at 00:58 least on the board of charity where i 01:00 have the honor to also serve 01:02 um 01:03 but i've also been a close follower and 01:06 also active participant in the world 01:08 health summit over the last 10 years at 01:09 least 01:11 and deadlift it's

01:13 it's not only a privilege to be up here 01:15 but it's really amazing what you've 01:16 created over the last 13 years because 01:18 what started as a small idea 01:21 with a big vision 01:22 today is much more than a small idea but 01:25 you truly 01:26 live up to 01:27 the name world health summit because it 01:30 has become a true reference every year 01:33 and a fixture in everybody's calendar so 01:35 congratulations for that 01:43 this past year the life sciences have 01:45 really emerged as a light in the 01:47 darkness 01:48 of the covet 19 pandemic 01:52 its value to society recognized to 01:55 degree rarely seen before certainly not 01:58 during my lifetime or at least working 02:00 in this industry 02:02 we have many reasons to be proud of and 02:04 you've heard it and it's really hard to 02:06 speak after all these people 02:08 i think unprecedented 02:10 collaboration 02:12 transparency but also taking 02:14 accountability for health across all 02:17 different 02:18 sectors and stakeholders

02:20 we've heard about the breathtaking speed 02:23 of discovery 02:24 regulatory approval 02:26 also manufacturing 02:28 and getting vaccines and other highly 02:30 effective medicines 02:32 to patients 02:34 in 02:35 a time we've never seen before and 02:36 hopefully i think this all will serve as 02:39 a foundation 02:41 a foundation to 02:44 a more sustained uh partnership to 02:46 tackle some of the other health crises 02:50 that 02:51 we've heard about 02:53 because 02:54 this very disruptive pandemic is still 02:56 just a small piece 02:59 of all the 03:00 remnants of health that we need to 03:02 tackle so while we may be celebrating 03:06 um 03:07 we as global players cannot ignore one 03:10 simple fact 03:12 not everybody could benefit from the 03:14 breakthroughs and collaboration that 03:16 we've seen and bill you i think you said 03:18 it very nicely um

03:21 it feels good for me like for everyone 03:23 else in this room 03:25 um 03:26 to have benefited over the past year 03:29 from innovation that helped 03:31 us to be today again in this room in 03:33 person rather than to be all behind 03:35 screens even though i um 03:38 i applaud the fact that you made this a 03:40 hybrid uh a hybrid conference which i 03:42 think is going to be most of the 03:43 conferences in the world regardless of 03:45 pandemics anyway 03:47 so 03:49 i am not really interested in the health 03:52 for a lucky few 03:54 i'm interested in health for all 03:57 our successes over these 18 months 04:00 should embolden us to really focus 04:02 much more closely on access innovation 04:05 and collaboration to unleash health for 04:07 all 04:09 especially 04:10 as we enter 04:11 on top of everything that's happening 04:13 really into a new era 04:15of science a lot of people talk about 04:17 the biorevolution in this context 04:20 so we've heard from bill a lot about

04:21 access so i'm not going to repeat 04:24 some of some of the examples that bill 04:27 has rightfully i think has given 04:29 but 04:31 health for all definitely means 04:33 patients around the world that get 04:36 access to medicines 04:38 at a price that they can afford and 04:40 making use of partnerships to ensure our 04:43 efforts 04:44 are sustainable over the long term 04:48 i could give you countless other 04:49 examples maybe also outside of europe 04:52 where we are today 04:53 where it is already difficult enough to 04:55 get access in equitable access across 04:57 all countries because i can guarantee 04:59 you there's a difference between having 05:01 access to novel 05:02 medicines in berlin 05:05 than it is in bucharest or in 05:08 in the ukraine for example 05:14 we also need to focus on what is 05:17 socially responsible outside of europe 05:19 and 05:20 ensure sustainable action there 05:23 we pledged 05:25 this past year to give 05:27 an additional 100 million women access

05:29 to contraceptive contraception in the 05:31 world we've invested 400 million this 05:33 year into new plants that are dedicated 05:35 to just produce uh long-acting 05:38 contraceptives uh for for women in low 05:40and middle-income countries uh we had 05:43 bill 05:44 uh um 05:46 uh bill gates this week in berlin i'm 05:48 sure many of you have met him uh this 05:49 week uh together with um 05:53 with him and and melinda gates 05:56 uh we're working very closely on 05:59 uh family planning initiatives as an 06:01 exam example for that 06:04 one of my preferred uh projects uh and 06:06 we're a leader in heart health as a 06:08 company and we've been invested in this 06:10 for a long time and and i hope one of 06:12 the anticoagulants that you had to take 06:15 maybe came from us so uh 06:17 well he raises his thumb so so glad to 06:19 help you out there bill 06:22 and today i must say for the first time 06:24 i didn't feel bad about never having to 06:26 having tried a skateboard 06:30 in terms of 06:31 of one of the things that that i feel 06:33 very strongly about is is our um because

06:36 it's a nice example it's a ghana health 06:37 initiative a heart initiative story uh 06:39 where we partner with the with the 06:41 german um 06:43 development initiative the gay eat set 06:45 so the 06:46 german institute for collaboration 06:49 to improve 06:50 risk assessment and management of 06:52 cardiovascular disease on-site in public 06:55 health facilities because i think this 06:57 is exactly it's not just about donating 06:59 medicines or giving medicines at a lower 07:01 price is also being onsite to uh to help 07:04 put this into practice 07:06 which i feel 07:08 is a nice example we've heard a lot 07:09 about innovation tonight 07:12 health for all 07:13 is certainly also embedding innovation 07:15 into all facets of the life sciences 07:17 ecosystem 07:19 making use of the current momentum 07:22 to tackle issues beyond covet 19. 07:25 we've seen the vaccines as the perfect 07:27 example 07:28 during this crisis 07:30 but innovations in the field of biotech 07:33 also radically upend

07:37 our view on many other diseases 07:38 especially ncds we can now think of 07:41 curing many of those disease not just 07:44 treating symptoms as we think forward 07:49 innovation and we tend to forget that 07:51 especially especially in the rich 07:52 countries 07:53 is also 07:55 sustainability at a totally different 07:56 level because those that take the leap 08:00 to drive innovation in a really 08:02 meaningful way and invest 08:05 and take the risk to invest in r d 08:07 will also 08:09 attain sustainability by creating job 08:11 security and creating prosperity for 08:13 those that take the investment i think 08:15 this is really important also for 08:17 uh 08:18 for these latitudes here 08:20 and um 08:22 for us therefore uh we're really taking 08:24 that leap us as a company buyer 08:28 in cell and gene therapy which to me is 08:30 one of these examples where really we're 08:32 going to make a difference hopefully uh 08:34 moving forward there's some 08:37 ultimately the the mrna vaccines are an 08:40 example for that cell in gene therapy i

08:42 always like to say if we had surveyed 08:44 two years ago 08:45 in the public would you be willing to 08:47 take a 08:48 gene 08:49 gene or cell therapy and inject it into 08:51 your body we would have probably had a 08:53 95 08:54 refusal rate i think this pandemic has 08:56 also opened many people's eyes to to 08:59 innovation in the way that was maybe not 09:02 possible before 09:05 but it's not just the industry that has 09:07 to innovate it's 09:08 across all 09:10 all the value chains starting with the 09:12 academia and university and again the 09:14 world health summit and i could only 09:15 applaud the initiative is a perfect 09:17 example for that because that left like 09:19 nobody else i think you've created a 09:21 network of university medicine it 09:23 started with very few and today 09:26 i think it's somewhere here behind me 09:27 you can see the example 09:29 of all those that participate 09:32 we need to make sure that the knowledge 09:35 that's created in our universities in 09:37 our academia is translated

09:39 translated before it goes into shiny 09:42 paper publications it's translated 09:44 ideally into patents 09:46 and into applications and that results 09:49 in new treatments medicines devices but 09:52 also medical procedures that's what we 09:54 need if we want to keep up with with 09:56 innovation 10:00 for us10:02at bayer innovation means uh 10:04 collaborating early and closely with 10:06 those partners 10:08 and making sure no one is left behind 10:13 so for everyone to benefit from 10:16 breakthrough in science we require 10:18 innovation-friendly policy regulatory 10:21 and economic frameworks we've heard 10:23 about this also in in bill's talk that 10:25 really understand the urgency of acting 10:28 now 10:29 as the ground swell of the biorevolution 10:32 picks up 10:34 sustainable health innovation must be 10:36 further elevated there is an opportunity 10:39 here10:40during germany's g7 presidency in 2022 10:44 normally henchbana would have 10:47 directed this at you we now need to also 10:49 talk to the incoming government in 10:50 germany about this specific 10:52 responsibility

10:54 to put health

10:56 and innovation

10:58 and sustainability sustainable health

11:01 firmly on the agenda

11:04 health for all

11:05 means also recognizing that a global

11:08 multi-partner effort is required in that

11:10 collaboration will be key

11:13 no industry player can do this alone no

11:16 ngo can do this alone no government can

11:18 do this alone

11:19 we can only do it together

11:22 and we've already seen over the past

11:24 pandemic

11:25 what can happen

11:27 when everyone in the healthcare

11:28 ecosystem is united by a joint purpose

11:32 so

11:34 what's new this time i think is how

11:36 society at large views the life sciences

11:39 in our collaborations

11:43 we gave

11:44 people

11:45 around the world new hope we inspired

11:48 new generations of innovators i can

11:50 imagine that many young people that

11:53 graduate now from high school and that

11:55 decide for college education they want

11:57 to go into science again because they

11:59 see what science can move and how 12:01 important science is in our lives we 12:03 inspired our community to think more 12:06 boldly12:08 collaboration will be key for achieving 12:10 health for all 12:12 in my vision i see a joint effort of 12:14 government 12:16 working hand-in-hand with science 12:17 organizations industry and civil society 12:19 and i can say 12:21 as an example because uh minister spahn 12:23 and i i think we've talked quite quite 12:25 often over the last two years he will 12:27 say not more often than he would have 12:29 liked probably 12:31 but 12:32 it's been that type of collaboration 12:34 that i would 12:35 that i would hope for to preserve as we 12:38 move forward 12:40 we're at the beginning 12:41 of a marvelous era in science and we 12:44 should be emboldened as i said before to 12:46 make health for all possible through 12:48 access innovation and collaboration 12:52 thank you for your attention